Identification of PTGR2 inhibitors as a new therapy for diabetes and obesity (Updated December 21, 2024).

The article discusses the potential use of PTGR2 inhibitors as a new therapy for diabetes and obesity. It highlights the role of PPAR gamma in regulating insulin sensitivity and energy balance, and the drawbacks of synthetic PPAR gamma ligands. The study suggests that inhibiting PTGR2 could be a promising approach to treating diabetes and obesity by increasing endogenous PPAR gamma ligands without the side effects associated with synthetic ligands. [Extracted from the article]